# Wanbury (NSE: WANBURY) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/WANBURY · Pivot · prices to 22 Oct 2026

Wanbury (NSE: WANBURY) closed at ₹185.66 on 22 Oct 2026, down 0.42% on the day. With a market capitalisation of ₹649 Cr, it ranks 1657th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 9.6× trailing earnings, against a return on equity of 51.5% in FY25. Over the past year the share price has fallen 25.7%. Its 52-week range is ₹161.50 (27 Jan 2026) to ₹358.85 (15 Jul 2026); the last close is 48.3% below the high. In Q1 FY26, the quarter ended 30 Jun 2025, revenue was ₹163 Cr (+24.5% year on year) and net profit ₹13 Cr (+1,197.1%), on a consolidated basis. Promoters held 43.02% of the company as of 30 Jun 2026; 86.69% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹185.66 |
| Market cap | ₹649 Cr |
| P/E (trailing) | 9.6 |
| ROE | 51.5% (FY25) |
| ROCE | 27.8% (FY25) |
| Debt to equity | 2.92 |
| 52-week high | ₹358.85 (15 Jul 2026) |
| 52-week low | ₹161.50 (27 Jan 2026) |
| 1-year return | −25.7% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY26 | ₹163 Cr | +24.5% | ₹13 Cr | +1,197.1% | ₹4.12 |
| Q4 FY25 | ₹172 Cr | +23.4% | ₹20 Cr | −39.8% | ₹6.18 |
| Q3 FY25 | ₹133 Cr | −8.3% | ₹1 Cr | −88.1% | ₹0.38 |
| Q2 FY25 | ₹161 Cr | +11.6% | ₹8 Cr | +9.0% | ₹2.44 |
| Q1 FY25 | ₹131 Cr | −10.4% | ₹1 Cr | −77.8% | ₹0.32 |
| Q4 FY24 | ₹139 Cr | +4.8% | ₹34 Cr | +3,197.1% | ₹10.28 |
| Q3 FY24 | ₹146 Cr | +15.7% | ₹10 Cr | — | ₹3.13 |
| Q2 FY24 | ₹144 Cr | +16.5% | ₹7 Cr | — | ₹2.25 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹600 Cr | ₹31 Cr |
| FY24 | ₹576 Cr | ₹56 Cr |
| FY23 | ₹500 Cr | −₹10 Cr |
| FY22 | ₹511 Cr | ₹81 Cr |
| FY21 | ₹393 Cr | −₹13 Cr |
| FY20 | ₹367 Cr | ₹64 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 43.02%
- Foreign institutions: 0.89%
- Domestic institutions: 0.06%
- Non-institutions: 56.03%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Kilitch Drugs (India)](https://app.pivotnow.in/stock/KILITCH) | ₹215.00 | ₹752 Cr | 24.2 | — |
| [Vikram Thermo](https://app.pivotnow.in/stock/VIKRAMTH) | — | ₹728 Cr | — | — |
| [Zim Laboratories](https://app.pivotnow.in/stock/ZIMLAB) | ₹133.50 | ₹715 Cr | 112.2 | — |
| [Valiant Laboratories](https://app.pivotnow.in/stock/VALIANTLAB) | ₹131.05 | ₹712 Cr | — | — |
| [Amanta Healthcare](https://app.pivotnow.in/stock/AMANTA) | ₹182.55 | ₹709 Cr | 42.2 | — |
| [Gaudium IVF and Women Health](https://app.pivotnow.in/stock/GAUDIUMIVF) | ₹95.11 | ₹692 Cr | 24.3 | — |

## Questions and answers

### What is the share price of Wanbury today?

Wanbury (NSE: WANBURY) last closed at ₹185.66 on 22 Oct 2026. Its 52-week high is ₹358.85 and its 52-week low is ₹161.50.

### What is the market cap of Wanbury?

Wanbury's market capitalisation is ₹649 Cr (₹649 Cr) at the 22 Oct 2026 close, ranking 1657th among the NSE companies Pivot tracks.

### What is the P/E ratio of Wanbury?

Wanbury trades at a trailing P/E of 9.6. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 42.2.

### What is the ROE and ROCE of Wanbury?

Return on equity was 51.5% in FY25 and return on capital employed was 27.8% in FY25 (consolidated figures).

### Is Wanbury a debt-free company?

No. Wanbury's debt-to-equity ratio was 2.92 in FY25, with total debt of ₹160 Cr.

### What were Wanbury's latest quarterly results?

For Q1 FY26 (quarter ended 30 Jun 2025), Wanbury reported revenue of ₹163 Cr, +24.5% year on year, and net profit of ₹13 Cr, +1,197.1% year on year.

### How has Wanbury stock performed over the last year?

Wanbury's share price has fallen 25.7% over the past year, −43.9% over three months and −18.4% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Wanbury?

As of 30 Jun 2026: promoters 43.02%, foreign institutions 0.89%, domestic institutions 0.06%, non-institutions 56.03%. 86.69% of promoter shares were pledged.

### Who are Wanbury's competitors?

The listed Pharma & Healthcare companies closest to Wanbury by market cap are Kilitch Drugs (India), Vikram Thermo, Zim Laboratories, Valiant Laboratories, Amanta Healthcare and Gaudium IVF and Women Health.

### Is Wanbury a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Wanbury's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on WANBURY against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.